Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
News and filings around Check-Cap Ltd. (NASDAQ: CHEK) trace the company’s evolution from a clinical stage medical diagnostics developer into a business centered on embodied artificial intelligence through its merger with MBody AI. Historically, Check-Cap announcements focused on its C-Scan® investigational device, an ingestible imaging capsule designed for preparation-free colorectal cancer screening, along with regulatory milestones and shareholder communications about its intellectual property and strategic alternatives.
More recent news is dominated by the definitive Agreement and Plan of Merger with MBody AI, a Nevada corporation described as a market leader in embodied artificial intelligence. Press releases and Form 6-K reports highlight shareholder approval of the merger, plans to rename the combined company “MBody AI Ltd.”, and the strategic rationale of combining Check-Cap’s legacy assets with MBody AI’s AI orchestration platform. Coverage includes details of the MBody AI Orchestrator™ platform, its hardware-agnostic architecture, and its deployment across Fortune 500 enterprises and blue-chip brands.
Investors following CHEK news can expect updates on merger progress, shareholder meeting outcomes, Nasdaq listing and compliance matters, and any financing or capital markets activity tied to the combined company’s growth strategy. Additional items include legal and governance-related press releases, as well as communications about Check-Cap’s acquisition of exclusive Ghost Kitchen franchise rights in New Jersey. This news feed offers a consolidated view of corporate developments, strategic transactions, and regulatory disclosures that shape the investment narrative for CHEK.
For those tracking the transition from medical diagnostics to embodied AI and related automation themes, the CHEK news page provides ongoing context on how Check-Cap and MBody AI present their business model, market positioning and long-term plans through official announcements and SEC-furnished materials.
Check-Cap Ltd. (NASDAQ: CHEK) provided an update on its C-Scan program in a letter from CEO Alex Ovadia. In 2022, the company enrolled over 300 patients in Israel and only 17 in the U.S. due to slow recruitment linked to state licensing for X-ray technology. The preliminary efficacy results from calibration studies did not meet goals, leading to a postponement of the powered portion of the U.S. pivotal study initially set for mid-2023. Check-Cap will conduct further data analysis, amend study protocols with the FDA, and implement a cost reduction plan to extend its cash runway.
Check-Cap Ltd. (NASDAQ: CHEK) reported financial results for Q3 2022 with a net loss of $4.7 million, compared to $4.2 million in Q3 2021. R&D expenses rose to $3.6 million from $3.0 million year-over-year, reflecting increased clinical and employee costs. The company continues efforts to expand U.S. site participation in its pivotal study for C-Scan, while experiencing slower-than-expected patient recruitment. Check-Cap executed a 1-for-20 reverse share split on November 23, 2022, resulting in approximately 5.8 million outstanding shares. Cash reserves were $46.0 million as of September 30, 2022.
Check-Cap Ltd. (NASDAQ: CHEK) reported its financial results for Q2 and six months ended June 30, 2022. The company initiated the U.S. pivotal study for C-Scan, a non-invasive colorectal cancer screening tool, at Mayo Clinic and NYU. Research and development expenses rose to $3.5 million in Q2, up from $2.8 million in 2021. Net losses increased to $4.8 million in Q2 compared to $3.9 million last year. Cash reserves decreased to $50.2 million. The company anticipates sufficient capital to fund operations through Q2 2024.
Check-Cap Ltd. (NASDAQ: CHEK) announced on June 23, 2022, that it received a 180-day extension from Nasdaq to comply with the minimum $1 bid price requirement, with a new deadline set for December 19, 2022. The company had previously failed to regain compliance after an initial notification in December 2021. If Check-Cap's share price reaches or exceeds $1 for 10 consecutive trading days before the deadline, it will regain compliance. Check-Cap is advancing its C-Scan® technology, a non-invasive colorectal cancer screening test.
Check-Cap Ltd. (NASDAQ: CHEK) reported financial results for Q1 2022, with a net loss of $5.8 million, up from $3.6 million in Q1 2021. The company initiated the U.S. pivotal study of its C-Scan® device in May 2022, aiming to enroll 1,000 subjects. R&D expenses rose to $4.1 million, influenced by increased headcount and clinical costs. General and administrative expenses also increased to $1.8 million. Cash reserves totaled $55.7 million as of March 31, 2022, ensuring operational funding through Q1 2024.
Check-Cap Ltd. (NASDAQ: CHEK) has initiated its U.S. pivotal trial for C-Scan®, a non-invasive screening test for colorectal cancer detection, at Mayo Clinic. Having received Institutional Review Board approval, the trial aims to enroll approximately 1,000 participants aged 50-75 across 15 sites. The study will assess C-Scan's accuracy in identifying polyp risks, with the first part focusing on calibration. Check-Cap's innovative approach seeks to enhance screening participation, addressing the common aversion to traditional colonoscopy procedures.
Check-Cap Ltd. (NASDAQ: CHEK) announced its Q4 and full-year 2021 financial results, revealing a net loss of $5.5 million for Q4 and $17.2 million for the full year. The company is advancing its C-Scan® test, aiming for a pivotal U.S. trial startup in April 2022. FDA approved an amended Investigational Device Exemption, facilitating this trial's initiation. Cash reserves stand at $51.9 million as of year-end 2021, bolstered by a $10 million offering in March 2022. Check-Cap believes it can sustain operations into Q1 2024, focusing on expanding colorectal cancer screening options.
Check-Cap Ltd. (NASDAQ: CHEK) has entered into agreements to sell 20 million ordinary shares and warrants to purchase 15 million additional shares for $10 million in gross proceeds. Each share is priced at $0.50, accompanied by a warrant exercisable at $0.65 for five years. Additionally, certain existing warrants from July 2021 will be modified to reduce their exercise price to $0.65 and extend their term to January 2025. The funds will be used to advance the clinical development of C-Scan®, a non-invasive screening test for colorectal cancer.
Check-Cap Ltd. (NASDAQ: CHEK) announced FDA approval for its amended Investigational Device Exemption (IDE) application, paving the way for a pivotal study of its C-Scan® technology. This screening test is designed to detect precancerous polyps in patients without the need for preparation, representing a significant advancement in colorectal cancer (CRC) diagnostics. The U.S. pivotal study will commence between March and April 2022, comprising two phases: calibration for average-risk individuals and a randomized comparison against traditional colonoscopy methods.
Check-Cap Ltd. (NASDAQ: CHEK) issued a letter from CEO Alex Ovadia highlighting 2021 achievements and updates on the C-Scan program. The FDA approved their Investigational Device Exemption (IDE) for a pivotal study, expected to begin in Q1 2022, focusing on device calibration and comparative performance against colonoscopy. The company enhanced manufacturing capacity and strengthened its clinical team. Financially, Check-Cap raised $31.8 million from a registered offering, ensuring operations funding into 2023. The FDA granted Breakthrough Device Designation, and the CE mark was renewed for C-Scan in Europe.